Travere Therapeutic TVTX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$1.71M (12 inflow days, 8 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 35.1% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 12.67% to 10.14% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +1,498,541 | 3.2% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +718,109 | 1.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +652,568 | 9.0% |
| Russell Investment Management, LLC | Mutual Fund | 2026/Q3 | +382,371 | 0.8% |
| Barclays PLC | Public Company | 2026/Q3 | +327,622 | 0.4% |
| Dimensional Fund Advisors | Mutual Fund | 2026/Q3 | +285,823 | 0.4% |
| Bank of America Corporation | Public Company | 2026/Q3 | +3,257,423 | 4.1% |
| Adage Capital Management, L.P. | Hedge Fund | 2026/Q3 | +1,592,356 | 2.7% |
| Marshall Wace LLP | Hedge Fund | 2026/Q3 | +1,154,671 | 1.4% |
| BNP Paribas Financial Markets SNC | Private Company | 2026/Q3 | +1,047,578 | 1.2% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +974,600 | 2.0% |
| Strategic Advisers LLC | Mutual Fund | 2026/Q3 | +955,114 | 1.0% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +774,071 | 1.5% |
| Rock Springs Capital Management LP | Hedge Fund | 2026/Q3 | +701,115 | 2.3% |
| Jane Street Group, LLC | Private Company | 2026/Q3 | +636,419 | 1.0% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 14 Oct 2026 | Eric Dube | Chief Executive Officer | Intent to Sell (Form 144) | -243,735 | $53.27 | – |
| 14 Oct 2026 | Eric Dube | Chief Executive Officer | Derivative Exercise and Sale | -243,735 | $55.02 | 152,367 |
| 16 Sep 2026 | Eric Dube | Chief Executive Officer | Intent to Sell (Form 144) | -108,493 | $63.48 | – |
| 16 Sep 2026 | Peter Heerma | Chief Commercial Officer | Intent to Sell (Form 144) | -8,282 | $63.48 | – |
| 16 Sep 2026 | Eric Dube | Chief Executive Officer | Derivative Exercise and Sale | -400,000 | $65.31 | 152,367 |
| 16 Sep 2026 | Peter Heerma | Chief Commercial Officer | Derivative Exercise and Sale | -258,189 | $65.07 | 61,430 |
| 15 Sep 2026 | William Rote | Chief Research Officer | Intent to Sell (Form 144) | -112,850 | $62.51 | – |
| 15 Sep 2026 | Eric Dube | Chief Executive Officer | Intent to Sell (Form 144) | -195,841 | $62.51 | – |
| 15 Sep 2026 | Peter Heerma | Chief Commercial Officer | Intent to Sell (Form 144) | -172,717 | $62.51 | – |
| 14 Sep 2026 | Elizabeth Reed | Chief Legal Officer, General Counsel & Secretary | Derivative Exercise and Sale | -37,500 | $65.31 | 105,389 |
| 14 Sep 2026 | William Rote | Chief Research Officer | Intent to Sell (Form 144) | -96,198 | $65.79 | – |
| 14 Sep 2026 | Christopher Cline | Chief Financial Officer | Automatic Disposition | -30,508 | $65.31 | 87,508 |
| 14 Sep 2026 | Christopher Cline | Chief Financial Officer | Derivative Exercise and Sale | -20,000 | $62.00 | 87,508 |
| 14 Sep 2026 | Eric Dube | Chief Executive Officer | Intent to Sell (Form 144) | -95,666 | $65.79 | – |
| 14 Sep 2026 | Peter Heerma | Chief Commercial Officer | Automatic Disposition | -25,000 | $65.31 | 61,430 |
| 14 Sep 2026 | Sandra Calvin | SVP & Chief Accounting Officer | Derivative Exercise and Sale | -5,375 | $63.66 | 42,353 |
| 14 Sep 2026 | Jula Inrig | Executive VP, Head of Research & Development and Chief Medical Officer | Automatic Disposition | -12,279 | $65.31 | 100,491 |
| 14 Sep 2026 | Jula Inrig | Executive VP, Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -32,395 | $62.62 | 100,491 |
| 9 Sep 2026 | Jeffrey Meckler | Independent Director | Derivative Exercise and Sale | -20,000 | $68.09 | 91,500 |
| 1 Sep 2026 | Christopher Cline | Chief Financial Officer | Open Market Disposition | -642 | $66.37 | 118,016 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 9,561,082 | 10.1% | 4.7 |
| 15 Oct 2026 | 10,913,583 | 11.6% | 5.2 |
| 30 Sep 2026 | 12,655,839 | 13.4% | 7.2 |
| 15 Sep 2026 | 12,955,933 | 13.7% | 10.4 |
| 31 Aug 2026 | 12,004,820 | 12.7% | 9.6 |
| 14 Aug 2026 | 11,943,638 | 12.7% | 5.7 |
No comments yet — be the first to weigh in on TVTX.
Sign in to join the discussion.